Document Detail

Cardioprotection from ischaemia-reperfusion injury by a novel Flavonol that reduces activation of p38 MAPK.
MedLine Citation:
PMID:  21371449     Owner:  NLM     Status:  Publisher    
Oxidative stress, activation of intracellular protein kinases and cardiomyocyte apoptosis are known mediators of cardiac ischaemia/reperfusion injury. The sites at which NP202, a novel water soluble pro-drug of 3',4'-dihydroxyflavonol (DiOHF), acts in this cascade to cause cardioprotection are unknown. In this study we examined the ability of NP202 to reduce infarct size after a prolonged period of ischaemia and reperfusion. In addition, we tested whether NP202 inhibits pro-apoptotic signalling, apoptosis and inflammation following myocardial ischaemia and reperfusion. Sheep were anaesthetised, the heart exposed and the 2(nd) branch of the left anterior descending coronary artery isolated. The artery was occluded for 3 h and, five minutes before 3 h of reperfusion was commenced, sheep were treated with intravenous vehicle or NP202. At the end of reperfusion infarct size was measured and normal left ventricle, non-infarcted area-at-risk and infarcted myocardium were collected to identify polymorphonuclear leukocytes (PMN) or apoptotic cells (TUNEL-positive), or assessed for activation of mitogen-activated protein kinase (MAPK) pathways by Western blot analysis. Compared with vehicle treatment, NP202 reduced infarct size (-20±4%, P<0.05) and decreased the number of PMNs and TUNEL-positive cells in the area-at-risk (-35±16% and -52±19%, respectively) and infarcted tissue (-57±9 and -81±5%, respectively, P<0.05). Furthermore, NP202 significantly reduced I/R-induced elevated p38 MAPK phosphorylation (by 67±4%, P<0.05) in the area-at-risk zone. In conclusion, the novel aqueous flavonol NP202 provided significant cardioprotection from clinically relevant prolonged myocardial ischaemia when administered just before reperfusion. Efficacy of NP202 was also associated with reduced p38 MAPK activation, inflammation and apoptotic cell death.
Colleen J Thomas; Dominic C H Ng; Nikolas Patsikatheodorou; Yuliardy Limengka; Matthew W K Lee; Ian A Darby; Owen L Woodman; Clive N May
Related Documents :
21972399 - Detection of lipid-core plaques by intracoronary near-infrared spectroscopy identifies ...
2572569 - Treatment for chronic chd.
21702299 - Frequency of pericardial effusion in patients with first myocardial infarction and its ...
21681619 - Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marro...
21635989 - Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasu...
22348339 - New equation for prediction of reverse remodeling after cardiac resynchronization therapy.
12555159 - Relation between left ventricular remodeling and clinical outcomes in heart failure pat...
21606749 - Contribution of fetal tricuspid regurgitation in first-trimester screening for major ca...
978639 - The incidence of myocardial infarction.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-2-28
Journal Detail:
Title:  European journal of pharmacology     Volume:  -     ISSN:  1879-0712     ISO Abbreviation:  -     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-3-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2010. Published by Elsevier B.V.
Howard Florey Institute, University of Melbourne, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnostic assays for anti-PM/Scl IgG antibodies: heterogeneity in antibody response or lack of stan...
Next Document:  2-Ethoxy-4,5-diphenyl-1,3-oxazine-6-one activates the Nrf2/HO-1 axis and protects against oxidative ...